Rare diseases
Investigational molecules
Locations
Back to Germany36 clinical trials in Buxtehude, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa
GermanyA study to evaluate the effectiveness of barzolvolimab in participants with cold urticaria and symptomatic dermographism
GermanyLong-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials
GermanyPhase 3 Study of Enpatoran in Patients with Active Cutaneous Lupus Erythematosus (with or without Systemic Disease)
GermanyGermanyStudy on Long-Term Safety and Efficacy of Litifilimab for Adults with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy
GermanyStudy Comparing Subcutaneous and Intravenous Nivolumab and Relatlimab for Patients with Untreated Metastatic or Unresectable Melanoma
GermanyStudy on the Safety and Effectiveness of IMA402, Tocilizumab, and Human Serum Albumin for Patients with Recurrent or Resistant Solid Tumors
GermanyStudy on Eblasakimab for Adults with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab
GermanyStudy Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Melanoma
GermanyStudy on the Effectiveness and Safety of ESK-001 and Apremilast for Patients with Moderate to Severe Plaque Psoriasis
GermanyStudy on the Long-Term Safety and Efficacy of Nemolizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis
GermanyThe busiest research cities in the country
What the registry says about research in the country
Clinical trials focusing on moderate to severe atopic dermatitis and plaque psoriasis, evaluating novel treatments including amlitelimab, eblasakimab, and ESK-001. Research aims to assess treatment efficacy and long-term safety profiles.
Multiple studies examining maintenance therapy and dose optimization in chronic skin conditions.
Comprehensive studies evaluating advanced melanoma treatments, including adjuvant immunotherapy trials with pembrolizumab and novel combination therapies. Research focuses on both early-stage and metastatic disease.
Emphasis on developing more effective treatment strategies for high-risk melanoma patients.
Investigating treatments for chronic urticaria, hidradenitis suppurativa, and bullous pemphigoid. Studies evaluate innovative therapies including remibrutinib and dupilumab for these challenging conditions.
Focus on improving treatment outcomes for patients with resistant disease forms.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
